These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 25528663)

  • 1. Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial.
    Fowler RA; Mittmann N; Geerts WH; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
    Trials; 2014 Dec; 15():502. PubMed ID: 25528663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
    Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
    JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial.
    Pineo G; Lin J; Stern L; Subrahmanian T; Annemans L
    J Hosp Med; 2012 Mar; 7(3):176-82. PubMed ID: 22058011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term therapy with enoxaparin or unfractionated heparin for venous thromboembolism in hospitalized patients: utilization study and cost-minimization analysis.
    Argenta C; Ferreira MA; Sander GB; Moreira LB
    Value Health; 2011; 14(5 Suppl 1):S89-92. PubMed ID: 21839908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.
    Dranitsaris G; Stumpo C; Smith R; Bartle W
    Am J Cardiovasc Drugs; 2009; 9(1):45-58. PubMed ID: 19178131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients.
    Li G; Cook DJ; Levine MAH; Guyatt G; Crowther M; Heels-Ansdell D; Holbrook A; Lamontagne F; Walter SD; Ferguson ND; Finfer S; Arabi YM; Bellomo R; Cooper DJ; Thabane L;
    Medicine (Baltimore); 2015 Sep; 94(36):e1479. PubMed ID: 26356708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.
    Deitelzweig SB; Becker R; Lin J; Benner J
    Thromb Haemost; 2008 Nov; 100(5):810-20. PubMed ID: 18989525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PROphylaxis for ThromboEmbolism in Critical Care Trial protocol and analysis plan.
    Cook D; Meade M; Guyatt G; Walter SD; Heels-Ansdell D; Geerts W; Warkentin TE; Cooper DJ; Zytaruk N; Vallance S; Berwanger O; Rocha M; Qushmaq I; Crowther M
    J Crit Care; 2011 Apr; 26(2):223.e1-9. PubMed ID: 21482348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
    Sarasin FP; Bounameaux H
    Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of dalteparin versus unfractionated heparin as venous thromboembolism prophylaxis in malignant gynecologic surgery.
    Wade WE; Spruill WJ
    Am J Ther; 2008; 15(6):512-5. PubMed ID: 19127133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients--a pharmacoeconomic analysis.
    Wilbur K; Lynd LD; Sadatsafavi M
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):454-65. PubMed ID: 20699258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Pharmacomechanical Catheter-Directed Thrombolysis Versus Standard Anticoagulation in Patients With Proximal Deep Vein Thrombosis: Results From the ATTRACT Trial.
    Magnuson EA; Chinnakondepalli K; Vilain K; Kearon C; Julian JA; Kahn SR; Goldhaber SZ; Jaff MR; Kindzelski AL; Herman K; Brady PS; Sharma K; Black CM; Vedantham S; Cohen DJ
    Circ Cardiovasc Qual Outcomes; 2019 Oct; 12(10):e005659. PubMed ID: 31592728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thromboprophylaxis using combined intermittent pneumatic compression and pharmacologic prophylaxis versus pharmacologic prophylaxis alone in critically ill patients: study protocol for a randomized controlled trial.
    Arabi YM; Alsolamy S; Al-Dawood A; Al-Omari A; Al-Hameed F; Burns KE; Almaani M; Lababidi H; Al Bshabshe A; Mehta S; Al-Aithan AM; Mandourah Y; Almekhlafi G; Finfer S; Abdukahil SA; Afesh LY; Dbsawy M; Sadat M
    Trials; 2016 Aug; 17(1):390. PubMed ID: 27488380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis.
    Avritscher EB; Cantor SB; Shih YC; Escalante CP; Rivera E; Elting LS
    Support Care Cancer; 2004 Jul; 12(7):531-6. PubMed ID: 14986076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Economic analysis of dalteparin use in knee surgery at Instituto Mexicano del Seguro Social].
    Arreola-Ornelas H; Rosado-Buzzo A; García-Mollinedo L; Dorantes Aguilar J; Muciño-Ortega E; Mould-Quevedo JF
    Cir Cir; 2012; 80(5):411-8. PubMed ID: 23351443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of dalteparin for preventing venous thromboembolism in abdominal surgery.
    Heerey A; Suri S
    Pharmacoeconomics; 2005; 23(9):927-44. PubMed ID: 16153135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.
    Amin AN; Lin J; Lenhart G; Schulman KL
    Thromb Haemost; 2009 Aug; 102(2):321-6. PubMed ID: 19652883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis.
    Gómez-Outes A; Rocha E; Martínez-González J; Kakkar VV
    Pharmacoeconomics; 2006; 24(1):81-92. PubMed ID: 16445305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
    Lynd LD; Goeree R; Crowther MA; O'Brien BJ
    Can J Clin Pharmacol; 2007; 14(2):e215-26. PubMed ID: 17652767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.